Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Microcap & Penny Stocks : Cryogenic Solutions Inc. (CYGS) -- Ignore unavailable to you. Want to Upgrade?

To: G.P. who wrote (3699)	7/28/1999 9:29:00 AM
From: G.P.	Read Replies (1) \| Respond to of 4028

Wednesday July 28, 8:19 am Eastern Time Company Press Release Cryogenic Solutions Inc. Files Form 10-SB with SEC to Become a Reporting Company HOUSTON--(BUSINESS WIRE)--July 28, 1999--Cryogenic Solutions Inc. (OTC BB:CYGS) has voluntarily filed a Form 10-SB Registration Statement with the United States Securities And Exchange Commission. The Company will also send all required Material Requests to the National Association of Securities Dealers Inc. (NASD) in order to comply with the January 1999 SEC approved OTC Bulletin Board Eligibility Rule. ''We are eager to comply with all regulatory agencies as we pursue the development and commercialization of our ssDNA Expression Vector,'' said Lawrence Wunderlich, Vice President of Finance for CYGS. ''This signifies another important step in the growth of the Company. We are committed to building shareholder value.'' CYGS has exclusive rights to the ssDNA vector technology developed by Dr. Charles Conrad of InGene Inc. The ssDNA vector can synthesize sequence specific single strands of DNA in vivo with or without flanking regions. This ability makes the ssDNA vector a most promising technology for overcoming the delivery barrier to an effective antisense gene therapy. This release contains forward-looking statements and is made under the protections afforded by the Securities Litigation Reform Act of 1995. Anyone who does not understand the overall antisense biotechnology referenced in this document or the significance of the specific CYGS technology is discouraged from investing in this company. -------------------------------------------------------------------------------- Contact: Cryogenic Solutions Inc., Houston Dell Gibson, 713/780-1399

To: G.P. who wrote (3699)	8/9/1999 10:07:00 AM
From: michael i olson	Read Replies (1) \| Respond to of 4028

More News Today & stock down???? Monday August 9, 8:13 am Eastern Time Company Press Release Dr. Skolnick to Take CYGS Helm HOUSTON--(BUSINESS WIRE)--Aug. 9, 1999--Cryogenic Solutions Inc. (OTC BB:CYGS - news) announced today that Malcolm Skolnick, PhD, JD will assume the duties of president and CEO on September first. Dr. Skolnick has previously served the company as a member of the board of directors and is currently of counsel to the company and chairman of the scientific advisory board. Current president and founder, Mike Skillern will return to applying full time to technology development. ''I've been working hard to get Dr. Skolnick on board as CEO so I can get back to what I do best,'' said Skillern. ''Dr. Skolnick has exactly the right set of skills and experience to establish our single stranded DNA expression vector as the antisense delivery platform, much like an operating system, that will enable gene therapy to become a practical reality.'' Skillern, whose principal field of interest is quantum mechanics, is pursuing a number of applications and patents of quantum state induction technologies, including induction control of biochemical processes. Although in recent years Dr. Skolnick's academic career has been in medicine and biotechnology, he earned his PhD in Theoretical Nuclear Physics at Cornell University in 1963 and was a member of the School of Mathematics at the Institute for Advanced Study, Princeton, N.J. Beginning in 1971 at the University of Texas Health Science Center, Dr. Skolnick served in various capacities including Professor of Biophysics, Director of the Neurophysiology Research Center, Director of the Office of Technology Management, and Professor of Technology and Health Law at the School of Public Health. He has conducted clinical trials related to pain management and detoxification from addictive drugs and holds patents on the devices developed in the research that led to those trials. Current teaching activities include ''The Food and Drug Administration'' and ''Healthcare Technology Assessment.'' Additionally, Dr. Skolnick earned a JD in 1986 at University of Houston School of Law and is a practicing patent attorney. His legal activities have included appearances before and submissions to the FDA, patent prosecution of U.S. and foreign cases, and the drafting and negotiation of contracts and license agreements to facilitate technology transfer for commercialization of intellectual property. This background uniquely qualifies Dr. Skolnick to help Skillern develop the technologies where Medicine and Physics intersect and it provides an invaluable perspective to the new leadership of CYGS. CYGS has developed an effective delivery mechanism for anti-sense oligodeoxyribonucleotides (ODN's). Combination of the CYGS single stranded DNA expression vector with the appropriate ODN for a specific disease or condition has been demonstrated in the laboratory. Dr. Skolnick explained, ''I believe the antisense technology heralds a paradigm shift from the chemical treatment of symptoms to the biopharmaceutical elimination of disease, and the CYGS vector is pivotal to the successful implementation of the technology. ''Molecular biology has brought a new dimension to medical science. The technology is constantly offering new methods to combat disease and extend life. Medical problems ranging from curing or preventing virus infections or cancer to methods which slow the aging process are being studied by delivering oligonucleotide sequences to the diseased or senescent cell.'' Dr. Skolnick continued, ''The impact of this technology on medical and pharmaceutical practice is already being felt. As the new anti-sense technology emerges from the laboratory and into clinical trials questions about regulation and delivery of the new medications must be addressed. Prescription of these new kinds of medication by physicians depends as always on the physician's knowledge of the underlying science and how that may be used for the benefit of the patient. ''The CYGS expression vector technology can be utilized with virtually any ODN that has been demonstrated effective in a particular cellular application. The expression vector by itself is a neutral quantity. Pharmaceutically speaking, it is an excipient, that is a neutral substance used to deliver an active compound.'' Dr. Skolnick concluded, ''Our company is at the triple threshold of assisting inventors demonstrating clinical effectiveness of their ODN's with our expression vector, achieving regulatory approval for a given ODN/vector combination, and finding a way to provide that therapeutic combination to patients. I see my role in CYGS as guiding the Company in crossing these thresholds.'' Dr. Skolnick's full CV is available in the company's website, cygs.net.